<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988479</url>
  </required_header>
  <id_info>
    <org_study_id>9638</org_study_id>
    <nct_id>NCT02988479</nct_id>
  </id_info>
  <brief_title>Out-of Pocket Payments in Patients With Lymphedema</brief_title>
  <acronym>Lymphorac2</acronym>
  <official_title>Out-of Pocket Payments in Patients With Primary Lymphedema in France and Inequities of Access to Healthcare</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary lymphedema is a chronic condition posing a high burden on patients. Clinical&#xD;
      guidelines emphasize the role of compression therapy by prescription medical devices. Even in&#xD;
      a mandatory publicly funded health insurance system, out-of-pocket payments (OOPP) may exist&#xD;
      due to the price and reimbursement setting processes. OOPP may threaten the equity of care&#xD;
      and drive patients to forgo care. The investigators aim was to analyze the distributive&#xD;
      effects of OOPP for primary lymphedema patients in France.&#xD;
&#xD;
      A prospective, multicenter study will be conducted in France in 2015 on patients with primary&#xD;
      lymphedema. Household ability to pay will be specified by net income and OOPP will be&#xD;
      assessed prospectively over 6 months for outpatient care (visits, drugs, medical devices,&#xD;
      nursing care, biological tests, imaging, physiotherapy and transportations). Both mandatory&#xD;
      and voluntary health insurance reimbursements will be considered. The investigators will&#xD;
      combine concentration curves and concentration indices to assess the distributive effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The mean monthly out-of-pocket payment as assessed by an online self-questionnaire</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">108</enrollment>
  <condition>Primary Lymphedema</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Out of pocket payments in patients</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients meeting the inclusion criteria will be included in each&#xD;
        participating centre during the inclusion phase&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient aged over six years, with primary lymphedema, regardless of the severity of&#xD;
             the disease;&#xD;
&#xD;
          -  Patient treated in one of the centres participating in the study;&#xD;
&#xD;
          -  Patient (and her legal representative for minors) who gave her written consent [or did&#xD;
             not refuse to participate, according to local Law];&#xD;
&#xD;
          -  Patient with Internet access and an active email address.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with concomitant chronic venous insufficiency;&#xD;
&#xD;
          -  Patient not covered by any health care insurance scheme;&#xD;
&#xD;
          -  People protected under the law.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregoire MERCIER, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

